Pharmaceutical Companies Engage in Intense Competition to Develop More Efficacious Less Toxic Therapies to Combat Breast Cancer.Business Editors/Health/Medical Writers PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif.--(BUSINESS WIRE)--May 3, 2004 In the past couple of years, breast cancer patients have become more apprehensive about using drugs that have minimal efficacy and harmful side effect profiles. To allay the fears of deteriorating quality of life and minimal survival benefits, pharmaceutical companies have responded by engaging in extensive clinical trials and aggressive product development campaigns to provide substantial therapeutic advantages to both early and late-stage breast cancer victims. New analysis from Frost & Sullivan (http://www.pharmaceuticals.frost.com), "U.S. Breast Cancer Therapeutics Markets," reveals that this market generated $2.02 billion in sales in 2003 and projects to reach $3.65 billion by 2010. If you are interested in a virtual brochure, which provides manufacturers, end-users and other industry participants an overview of the latest analysis of the "U.S. Breast Cancer Therapeutics Markets," send an e-mail to Danielle White Danielle Marie White (born February 2, 1992 in Cincinnati, Ohio) is an American singer who was raised in Bradenton, Florida. In 2003, White appeared on the reality television series American Juniors , Corporate Communications Corporate communications is the process of facilitating information and knowledge exchanges with internal and key external groups and individuals that have a direct relationship with an enterprise. , at dwhite@frost.com with the following information: your full name, company name, title, telephone number, fax number and e-mail. Upon receipt of the above information, an overview will be sent to you via e-mail. "Future treatment strategies will focus on drugs with clear therapeutic potential and minimal side effect profiles. Thereby, specialized biologic therapies such as angiogenesis inhibitors, vaccines and monoclonal antibodies This is a list of monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies"). can make an impact through targeted mechanisms of action and minimized toxicity," says Frost & Sullivan research analyst Curt A. Herberts III. In the hormonal therapeutic sector, many aromatase inhibitors, such as Aromasin and Femara, are currently undergoing trials to test their advantages over tamoxifen citrate tamoxifen citrate (t  mok´s in the adjuvant adjuvant /ad·ju·vant/ (aj?dbobr-vant) (a-joo´vant)1. assisting or aiding. 2. a substance that aids another, such as an auxiliary remedy. 3. and extended adjuvant settings for breast cancer. Such intense research is likely to radically alter overall treatment procedures within the hormone receptor-positive breast cancer market. Apart from these drugs, chemoprotectant agents are likely to play a significant role in the cytotoxic cy·to·tox·ic adj. Of, relating to, or producing a toxic effect on cells. cy  to·tox·ic therapeutic market. These therapeutics can ease chemotherapy's harsh side effects Side effectsEffects of a proposed project on other parts of the firm. of neutropenia Neutropenia Definition Neutropenia is an abnormally low level of neutrophils in the blood. Neutrophils are white blood cells (WBCs) produced in the bone marrow that ingest bacteria. , nausea, vomiting vomiting, ejection of food and other matter from the stomach through the mouth, often preceded by nausea. The process is initiated by stimulation of the vomiting center of the brain by nerve impulses from the gastrointestinal tract or other part of the body. , diarrhea and anemia and allow for higher dosage payloads, which will enact greater tumor suppression. Additionally, multiple chemopotentiators, which enhance the toxic effects of chemotherapeutics directly on tumor cells, await FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval in the next couple of years. The extensive benefits of these new discoveries will prove to be the pharmaceutical industry's passport into new therapeutic domains. As companies demonstrate positive clinical trial results, they will experience increased approvals, a widening patient base, and increased therapeutic duration of use. All of these factors will directly translate into increase in sales, larger profit margins and stronger positions in the market. "In the future, we will look for aggressive clinical trial efforts and extensive licensing activities between biotech and large pharmaceutical companies to bring the new wave of cytotoxic, hormonal and biologic treatments to market. Such new age medicines will impact not only the way we think about disease, but also the manner in which women live their lives in the treatment setting following initial diagnosis. The pharmaceutical companies that take advantage of the significant growth in targeted therapeutic developments will find exceptional competitive advantages in the years to come," states Curt Herberts. The "U.S. Breast Cancer Therapeutics Analysis," a part of the Pharmaceuticals Monitor Service and Cancer Therapeutics Monitor Service subscription, analyzes the market and provides competitive information to assess the state of the industry and current market shares. Segments such as biologic, cytotoxic and hormonals are analyzed and comprehensive information is provided on the numerous products offered by competitors. The research also provides detailed patient forecasts. Interviews are available to the press. Frost & Sullivan, an international growth consultancy, has been supporting clients' expansion for more than four decades. Our market expertise covers a broad spectrum of industries, while our portfolio of advisory competencies includes custom strategic consulting, market intelligence and management training. Our mission is to forge partnerships with our clients' management teams to deliver market insights and to create value and drive growth through innovative approaches. Frost & Sullivan's network of consultants, industry experts, corporate trainers and support staff spans the globe with offices in every major country. "U.S. Breast Cancer Therapeutics Markets" A578-52 The following is a key list of industry participants: AstraZeneca; Aventis; Barr Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Genentech Inc.; Novartis AG Novartis AG Swiss pharmaceutical company. It was formed through the 1996 merger of two Swiss firms: Ciba (see Ciba-Geigy) and Sandoz, a chemical company with interests in pharmaceuticals, nutrition, and agriculture. ; Ortho Biotech; Pfizer Inc.; Shire US Inc.; YM Biosciences YM BioSciences is a biotech company towards finding cancer cures. Its recent work includes EGF receptor monoclonal antibody called TheraCIM hR3, which has been given orphan status by the Food and Drug Administration (FDA). It is targeted to treatment of gliomas. Inc. Keywords in this release: U.S., breast cancer, therapeutics, adjuvant treatment, cytotoxic, antiangiogenesis, vaccines, monoclonal antibodies, aromatase inhibitors, Aromasin, Femara, tamoxifen citrate, extended adjuvant setting, antiemetics, neutropenia, chemosensitizing agents, chemotherapy, polychemotherapy, monotherapy, taxanes, vinca alkaloids vinca alkaloids a group of alkaloids, including vinblastine and vincristine, extracted from the periwinkle plant (Vinca rosea), which arrest cell division in metaphase by disrupting the microtubules that form the spindle apparatus; used as antineoplastic agents. , monoclonal antibodies, non-cross resistant drugs, research, information, market, trends, technology, service, forecast. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion